An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Recruiting

Phase 3

PelacarsenAn Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Sponsor:

Novartis Pharmaceuticals

Code:

NCT07517263

Conditions

Cardiovascular Disease and Lipoprotein(a)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Pelacarsen (TQJ230)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-22. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-05-18.